Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Salix Pharmaceuticals to raise $55 million

This article was originally published in Scrip

Executive Summary

Salix Pharmaceuticals priced an offering of $55 million convertible senior notes to institutional buyers due in 2028. The gastrointestinal (GI) drug developer plans to use the offering to develop and commercialise candidates and new indications for rifaximin, as well as for in-licensing and acquisitions and general working capital. Rifaximin is a non-systemic, GI-selective oral antibiotic and is used in several GI conditions including Crohn's disease, irritable bowel syndrome, and infectious diarrhoea. The product had second-quarter sales of $14 million (+18%), while the firm's revenues were $41.1 million, down by 38% because of the launch of an authorised generic version of Colazal (balsalazide disodium).






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts